TRACON PHARMACEUTICALS INC (TCON)
US89237H3084 - Common Stock
We assign a fundamental rating of 3 out of 10 to TCON. TCON was compared to 588 industry peers in the Biotechnology industry. While TCON seems to be doing ok healthwise, there are quite some concerns on its profitability. TCON is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TCON was profitable.
TCON had a positive operating cash flow in the past year.
In the past 5 years TCON always reported negative net income.
TCON had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -35.54%, TCON is doing good in the industry, outperforming 65.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.54% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-97.71%
ROA(5y)-92.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TCON does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TCON does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TCON has been increased compared to 1 year ago.
Compared to 5 years ago, TCON has more shares outstanding
TCON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -34.27, we must say that TCON is in the distress zone and has some risk of bankruptcy.
TCON has a Altman-Z score of -34.27. This is amonst the worse of the industry: TCON underperforms 91.78% of its industry peers.
There is no outstanding debt for TCON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 0 | ||
| Altman-Z | -34.27 |
ROIC/WACCN/A
WACC68.55%
2.3 Liquidity
A Current Ratio of 0.89 indicates that TCON may have some problems paying its short term obligations.
With a Current ratio value of 0.89, TCON is not doing good in the industry: 90.07% of the companies in the same industry are doing better.
TCON has a Quick Ratio of 0.89. This is a bad value and indicates that TCON is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of TCON (0.89) is worse than 89.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.89 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 817.14% over the past year.
The Revenue has been growing by 32.05% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)817.14%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q164.52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y32.05%
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to decrease by -15.22% on average over the next years. This is quite bad
Based on estimates for the next years, TCON will show a very strong growth in Revenue. The Revenue will grow by 68.33% on average per year.
EPS Next Y-102.34%
EPS Next 2Y-42.01%
EPS Next 3Y-82.81%
EPS Next 5Y-15.22%
Revenue Next Year-100%
Revenue Next 2Y-59.18%
Revenue Next 3Y37.57%
Revenue Next 5Y68.33%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
TCON is valuated cheaply with a Price/Earnings ratio of 0.19.
Based on the Price/Earnings ratio, TCON is valued cheaper than 99.83% of the companies in the same industry.
When comparing the Price/Earnings ratio of TCON to the average of the S&P500 Index (25.25), we can say TCON is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for TCON. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.19 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of TCON indicates a rather cheap valuation: TCON is cheaper than 99.83% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1.21 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as TCON's earnings are expected to decrease with -82.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-42.01%
EPS Next 3Y-82.81%
5. Dividend
5.1 Amount
TCON does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TRACON PHARMACEUTICALS INC
NASDAQ:TCON (4/25/2024, 9:04:36 AM)
1.95
+0.06 (+3.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.45M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.19 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.54% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.89 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)817.14%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-102.34%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y